Comparative Pharmacology
Head-to-head clinical analysis: TRIPHASIL 21 versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPHASIL 21 versus VIORELE.
TRIPHASIL-21 vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus to impair sperm penetration and endometrial receptivity.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
One tablet orally daily for 21 days, followed by 7 drug-free days. Each tablet contains levonorgestrel 0.05 mg and ethinyl estradiol 0.03 mg (days 1-6), levonorgestrel 0.075 mg and ethinyl estradiol 0.04 mg (days 7-11), and levonorgestrel 0.125 mg and ethinyl estradiol 0.03 mg (days 12-21).
50 mg orally once daily
None Documented
None Documented
Levonorgestrel: 10-45 hours (terminal, biphasic); ethinyl estradiol: 10-27 hours (terminal, triphasic). Clinical context: Steady state reached after 7-14 days with daily dosing.
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Renal: 30-50% (ethinyl estradiol and levonorgestrel metabolites as glucuronide and sulfate conjugates). Fecal: 30-50% (biliary excretion of unconjugated metabolites). Unchanged drug: negligible.
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive